Mois : avril 2019

Bibliographie : Cannabinoïdes et autismes , GRECC, Dr Christian Sueur, mars 2019

Bibliographie : Cannabinoïdes et TSA/TED/psychoses infantiles. Dr Christian Sueur, GRECC, mars 2019. (2e version) ARAN A., CASSUTO H., LUBOTZKY : Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasability Study (P3.318), Neurology Genetics, 2018, 90 (15). http://n.neurology.org/content/90/15_Supplement/P3.318 ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasability Study, Journal of Autism and Developmental Disorders, 2018 Oct 31. Doi : 10.1007/s10803-018-3808-2 BARCHEL D., STOLAR O., De-HAAN T., ZIV-BARAN T., SABAN N., FUCHS D.O., KOREN G., BERKOVITCH M. : Oral Cannabidiol Use in Children With Auttism Spectrum Disorder to Treat Related Symptoms [...]

Lire la suite

Endocannabinoid-Mediated Control of Synaptic Transmission, Masanobu KANO et al., 2009

Endocannabinoid-Mediated Control of Synaptic Transmission Masanobu KANO, Takako OHNO-SHOSAKU, Yuki HASHIMOTODANI, Motokazu UCHIGASHIMA, and Masahiko WATANABE Physiological Reviews, 2009, 89, 1, 309-380. https://doi.org/10.1152/physrev.00019.2008 I. Introduction 310 II. Cannabinoid Receptors 311 A. CB1 receptor 311 B. CB2 receptor 315 C. “CB3” receptor 315 D. TRPV1 receptor 317 E. GPR55 receptor 317 III. CB1 Receptor Signaling 317 A. Intracellular signaling pathways 317 B. Suppression of transmitter release 318 C. Morphological changes 318 IV. Biochemistry of Endocannabinoids 318 A. Endocannabinoids 318 B. Biosynthesis of anandamide 319 C. Biosynthesis of 2-AG 320 D. Degradation of endocannabinoids 321 E. Endocannabinoid transport 321 F. Lipid raft 322 V. Endocannabinoid-Mediated Short-Term Depression 322 A. Endocannabinoid as a retrograde messenger 322 B. eCB-STD in various brain regions 324 C. Mechanisms of ecb-std 334 VI. [...]

Lire la suite

Cannabis thérapeutique : les promesses de l’herbe, INTERCEPTION, France Inter, dimanche 7 avril 2019

INTERCEPTION, France Inter, dimanche 7 avril 2019 par Philippe Bardonnaud , Vanessa Descouraux , Géraldine Hallot Cannabis thérapeutique : les promesses de l'herbe https://www.franceinter.fr/emissions/interception/interception-07-avril-2019   Une excellente émission, sur le cannabis thérapeutique, essentiellement en Israël, ou il est question du "grand retard français" (et une interview de notre confrère Nicolas AUTHIER)   à écouter absolument  

Lire la suite

Interview avec Yann Bisiou : l’amende cannabis effective mais pour l’instant pas applicable, Camille Lezaun, Newsweed, 26 mars 2019

Interview avec Yann Bisiou : l’amende cannabis effective mais pour l’instant pas applicable Contraventionnalisation du cannabis en France 26 mars 2019 Camille Lezaun En janvier, l’Assemblée Nationale approuvait le projet de loi de réforme de la justice dont l’article 58 consacre la contraventionalisation du délit d’usage de stupéfiants. L’ensemble du projet a toutefois fait l’objet d’une saisine du Conseil Constitutionnel par des parlementaires, suspendant alors la promulgation de la loi. Le Conseil a rendu son avis la semaine dernière en rejetant tous les griefs opposés à l’article 58. En d’autres termes, ça y est, « l’amende Poulliat » (du nom de son créateur)  est [...]

Lire la suite

Médicaments pour le traitement de la dépendance au cannabis, Bibliothèque COCHRANE, 28 janvier 2019

Médicaments pour le traitement de la dépendance au cannabis Bibliothèque COCHRANE, 28 janvier 2019 Nielsen S, Gowing L, Sabioni P, Le Foll B https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008940.pub3/full/fr#CD008940-abs-0002   Contexte L'usage de cannabis est relativement courant et répandu mondialement. Dans la plupart des régions du monde, les usagers de cannabis sont en demande croissante de traitements. La tendance à la dépénalisation ou à la légalisation de l'usage du cannabis dans certains pays va probablement faire perdurer cette tendance. Actuellement, il n'existe pas de traitements spécifiques pour la consommation de cannabis. Cette revue visait à évaluer l'efficacité et l'innocuité des médicaments pour le traitement de la dépendance au cannabis. Date de la [...]

Lire la suite

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age, José A. Crippa et al., 2018

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age José A. Crippa, Francisco S. Guimaraes, Alline C. Campos, Antonio W. Zuardi Frontiers in Immunology, 21 september 2018. https://doi.org/10.3389/fimmu.2018.02009   Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. Methods: A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. Results: CBD was shown [...]

Lire la suite

The Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder, Yann Chye et al., 2019

The Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder Yann Chye, Erynn Christensen, Nadia Solowij, and Murat Yücel Frontiers in Psychiatry, 19 February 2019, doi: 10.3389/fpsyt.2019.00063   Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol [...]

Lire la suite

Endocannabinoid Signaling in Autism, Bhismadev Chakrabarti et al., 2015

Endocannabinoid Signaling in Autism Bhismadev Chakrabarti, Antonio Persico, Natalia Battista, Mauro Maccarrone Neurotherapeutics, 2015, Volume 12, Issue 4, 837-847. DOI 10.1007/s13311-015-0371-9 Abstract Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of [...]

Lire la suite

Autism Spectrum Disorder and Cannabidiol : Have We Seen This Movie Before ?, Carlos A. Salgado and Daniel Castellanos, 2018

Autism Spectrum Disorder and Cannabidiol : Have We Seen This Movie Before? Carlos A. Salgado,  and Daniel Castellanos, Glob Pediatr Health. 2018; 5: 2333794X18815412 doi: 10.1177/2333794X18815412 Received July 5, 2018. Received revised October 9, 2018. Accepted for publication October 23, 2018.   Recently, the use of marijuana and cannabidiol (CBD) in children with autism spectrum disorder (ASD) has received increasing attention in the media with articles sensationally titled “Marijuana may be a miracle treatment for children with autism.” An absence of empirical data appears to have resulted in a growing body of anecdotal evidence espousing the benefits of CBD for children with ASD. Some reports describe the [...]

Lire la suite

Cannabinoids for Behavioral Problems in Children With ASD (CBA), ClinicalTrials.gov Identifier: NCT02956226, 2016-2018

Cannabinoids for Behavioral Problems in Children With ASD (CBA) ClinicalTrials.gov Identifier : NCT02956226 Recruitment Status : Completed First Posted : November 7, 2016 Last Update Posted : December 27, 2018  https://clinicaltrials.gov/ct2/show/NCT02956226?term=cannabidiol&cond=Autism+Spectrum+Disorder Sponsor : Shaare Zedek Medical Center Information provided by (Responsible Party) : Dr. Adi Aran, Shaare Zedek Medical Center Study Description Brief Summary : This study aims to assess the safety, tolerability and efficacy of cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio, BOL Pharma, Israel] for behavioral problems in children and youth with ASD. Condition or disease Intervention/treatment Phase Autistic Disorder Drug: Cannabinoids - 99% pure cannabinoids mixDrug: PlaceboDrug: Cannabinoids - whole plant extract Study Design Study [...]

Lire la suite